How to buy Kazia Therapeutics shares | A$0.805

Kazia Therapeutics Limited is a biotechnology business based in Australia. Kazia Therapeutics shares (KZA) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.805 – an increase of 0.63% over the previous week. Kazia Therapeutics has a trailing 12-month revenue of around $988,110.

How to buy shares in Kazia Therapeutics

1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
3. Search for Kazia Therapeutics . Find the share by name or ticker symbol: KZA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kazia Therapeutics reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At today's price of $0.805, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
6. Check in on your investment. Congratulations, you own a part of Kazia Therapeutics . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

🧪How we chose these brokers

For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.

How has coronavirus impacted Kazia Therapeutics 's share price?

Since the stock market crash in March caused by coronavirus, Kazia Therapeutics 's share price has had significant positive movement.

Its last market close was $0.805, which is 21.12% up on its pre-crash value of $0.635 and 109.09% up on the lowest point reached during the March crash when the shares fell as low as $0.385.

If you had bought $1,000 worth of Kazia Therapeutics shares at the start of February 2020, those shares would have been worth $713.11 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,319.67.

Kazia Therapeutics share price

Use our graph to track the performance of KZA stocks over time.

Kazia Therapeutics shares at a glance

• Key figures

Information last updated 2020-10-15.

Latest market close	AUDA$0.805
52-week range	AUDA$0.37 - AUDA$1.235
50-day moving average	AUDA$0.9384
200-day moving average	AUDA$0.6179
Target price	AUDA$0.22
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	AUDA$-0.179

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

• Brokerage - AU shares: From AUD 5 or 0.05%
• Brokerage - US shares: USD 0
• Sign-up process: Instant
• Support - After hours: Yes

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Kazia Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kazia Therapeutics Limited by TradingView

Kazia Therapeutics price performance over time

Historical closes compared with the close of A$0.805 on 2020-10-20

1 week (2020-10-10)	N/A
1 month (2020-09-21)	-14.81%
3 months (2020-07-17)	61.00%
6 months (2020-04-17)	85.06%

1 year (2019-10-18)	67.71%
2 years (2018-10-19)	109.09%
3 years (2017-10-19)	96.34%
5 years (2015-10-19)	-48.06%

Kazia Therapeutics financials

Revenue TTM	$988,110
Gross profit TTM	$988,110
Return on assets TTM	-34.45%
Return on equity TTM	-88.05%
Profit margin	0%
Book value	0.149
Market capitalisation	$59.9 million

TTM: trailing 12 months

Kazia Therapeutics share dividends

We're not expecting Kazia Therapeutics to pay a dividend over the next 12 months.

Have Kazia Therapeutics 's shares ever split?

Kazia Therapeutics 's shares were split on a 1:10 basis on 16 November 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kazia Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Kazia Therapeutics shares which in turn could have impacted Kazia Therapeutics 's share price.

Kazia Therapeutics share price volatility

Over the last 12 months, Kazia Therapeutics 's shares have ranged in value from as little as $0.37 up to $1.235. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Kazia Therapeutics 's is 2.133. This would suggest that Kazia Therapeutics 's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Kazia Therapeutics overview

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Frequently asked questions

• What percentage of Kazia Therapeutics is owned by insiders or institutions?

  Currently 19.879% of Kazia Therapeutics shares are held by insiders and 10.064% by institutions.

• When does the fiscal year end for Kazia Therapeutics ?

  Kazia Therapeutics 's fiscal year ends in June.

• Where is Kazia Therapeutics based?

  Kazia Therapeutics 's address is: Three International Towers, Sydney, NSW, Australia, 2000

• What is Kazia Therapeutics 's ISIN number?

  Kazia Therapeutics 's international securities identification number is: AU000000KZA9